Hyderabad-based Indian multinational maker of generic drugs, APIs, biologics and vaccines, sold in over 150 countries.
aurobindo.comFounded
1986
Headquarters
Hyderabad, Telangana, India
Industry
Pharmaceuticals
Employees
10,001+Revenue (FY26)
Rs 33,653 crore
Market Cap
Rs 91,749 crore
Listed on
NSE: AUROPHARMA, BSE: 524804
Managing Director
K. Nityananda Reddy
Website
aurobindo.comCIN
L24239TG1986PLC015190
Aurobindo Pharma Limited is an Indian multinational pharmaceutical company headquartered in Hyderabad, Telangana. It was founded in 1986 by V. Ramprasad Reddy and K. Nityananda Reddy and incorporated on 26 December 1986. The company makes generic drugs, active pharmaceutical ingredients, biologics, vaccines and related products, and sells across more than 150 countries.
The company is publicly listed in India, trading as AUROPHARMA on the NSE and under code 524804 on the BSE, with corporate identification number L24239TG1986PLC015190. For the fiscal year ended March 2026 it reported consolidated revenue of about Rs 33,653 crore, and its market capitalization stood near Rs 91,749 crore as of 21 July 2026.
Leadership sits with Vice Chairman and Managing Director K. Nityananda Reddy, who has led operations since the company's founding. Mangalam Ramasubramanian Kumar serves as Independent Director and Non-Executive Chairman, Subramanian Santhanam is Chief Financial Officer, and M. Madan Mohan Reddy is a Whole-time Director. Alongside its Hyderabad base, the company runs a US arm headquartered in East Windsor, New Jersey.
Vice Chairman & Managing Director
Independent Director & Non-Executive Chairman
Chief Financial Officer
Whole-time Director
Interview experience
Favourable (7 out of 10)
Interview difficulty
Medium (6 out of 10)
Interview process length
About a day to a month
Practice real questions and get instant feedback before you walk in.
Q: Are you willing to work overtime?
A: Manufacturing sites run on shifts, so be honest about your availability while signalling flexibility. Confirm you can cover extra hours when production needs it, and ask how overtime is scheduled and compensated.
Q: Can you lift 50 pounds and stand on your feet for 8 hours?
A: This checks whether you can meet the physical demands of the role. Answer directly about your ability, and mention any relevant hands-on warehouse or manual work you've done.
Q: Behavioural questions and technical questions based on your role.
A: Expect a mix of situational questions and role-specific technical checks. Use the STAR method for behavioural questions and keep technical answers grounded in what you've actually done.
Q: Explain the employee life cycle and the sourcing and recruitment process.
A: Walk through the stages from attraction and hiring to onboarding, development, retention and exit. For sourcing, cover how you find, screen and move candidates through the funnel.
Practice real questions and get instant feedback before you walk in.
1 to 8 yrs
₹3.8L to ₹4.2L/yr
1,000 Salaries submitted
0 to 9 yrs
₹5.4L to ₹5.9L/yr
242 Salaries submitted
1 to 13 yrs
₹5.6L to ₹6.3L/yr
182 Salaries submitted
1 to 10 yrs
₹5.2L to ₹5.7L/yr
165 Salaries submitted
5 to 12 yrs
₹5L to ₹5.5L/yr
142 Salaries submitted
1 to 10 yrs
₹5.1L to ₹5.7L/yr
128 Salaries submitted
Compare your salary against real submissions and open roles.
2 to 6 years • Naidupeta, Andhra Pradesh • Full-time
2 to 8 years • Naidupeta, Andhra Pradesh • Full-time
2 to 8 years • Naidupeta, Andhra Pradesh • Full-time
2 to 8 years • Naidupeta, Andhra Pradesh • Full-time
4 to 8 years • Naidupeta, Andhra Pradesh • Full-time
3 to 8 years • Jadcherla, Telangana • Full-time
Tailor your resume to Aurobindo Pharma roles in minutes.
July 13, 2026
Aurobindo subsidiary incorporates PT Auro Pharm Indonesia
Aurobindo's step-down subsidiary PT Aurogen Pharma Indonesia incorporated a new wholly owned manufacturing entity, PT Auro Pharm Indonesia, on July 1, 2026 with an initial IDR 20 billion investment. The move expands the company's manufacturing footprint in Indonesia.
#expansion #manufacturing #Indonesia
View postMay 21, 2026
Aurobindo Q4 FY26 net profit up 2% to Rs 921 crore
Consolidated net profit rose about 2% year on year to Rs 921 crore in the March 2026 quarter, with revenue from operations up 5.6% to Rs 8,853 crore. Full-year FY26 revenue crossed Rs 33,653 crore, up 6.1%.
#earnings #Q4FY26 #results
View postMay 7, 2026
Aurobindo completes Rs 800 crore share buyback
The company completed its tender-route buyback of 54,23,728 equity shares at Rs 1,475 per share, utilising about Rs 800 crore. The offer was oversubscribed roughly 5.43 times.
#buyback #capitalreturn #shareholders
View postMay 1, 2026
CuraTeQ's Bevqolva biosimilar gets Health Canada nod
Aurobindo's subsidiary CuraTeQ Biologics received a Notice of Compliance from Health Canada for Bevqolva, a bevacizumab biosimilar to Avastin, in 100 mg and 400 mg presentations. Two further biosimilar applications remain under review with Health Canada.
#biosimilars #regulatory #Canada
View postApril 17, 2026
Aurobindo wins USFDA nod for generic Ravicti
The company received USFDA final approval for Glycerol Phenylbutyrate Oral Liquid 1.1 g/mL, a generic of Horizon Therapeutics' Ravicti used for urea cycle disorders. The product carries an estimated US market size of about USD 50.2 million.
#USFDA #approval #generics
View postAurobindo Pharma makes generic drugs, active pharmaceutical ingredients, biologics and vaccines. It sells across more than 150 countries from its base in Hyderabad, India.
